Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Cancer|June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitorsMingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Oncotarget|November 5, 2017
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancerMichele R Wing, Julie W Reeser, Amy M Smith, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Cancer|June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitorsMingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Oncotarget|November 5, 2017
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancerMichele R Wing, Julie W Reeser, Amy M Smith, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Pageof 16